WO2020228513A1 - 基于苯并吡喃结构的新型cdk9抑制剂、其制备方法及应用 - Google Patents

基于苯并吡喃结构的新型cdk9抑制剂、其制备方法及应用 Download PDF

Info

Publication number
WO2020228513A1
WO2020228513A1 PCT/CN2020/086917 CN2020086917W WO2020228513A1 WO 2020228513 A1 WO2020228513 A1 WO 2020228513A1 CN 2020086917 W CN2020086917 W CN 2020086917W WO 2020228513 A1 WO2020228513 A1 WO 2020228513A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
compound
dmso
cancer
ppm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2020/086917
Other languages
English (en)
French (fr)
Inventor
卞金磊
李志裕
赵腾腾
王举波
吴体智
田于成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Publication of WO2020228513A1 publication Critical patent/WO2020228513A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to the field of biomedicine, and specifically includes a series of novel CDK9 inhibitor derivatives of benzofuran structure and their uses, and includes compounds as CDK9 inhibitors, pharmaceutically acceptable salts, esters, and solvents of the above compounds Compounds or prodrugs, and the use of pharmaceutical compositions of the above-mentioned compounds.
  • Cyclin-dependent kinases are a member of the serine/threonine kinase family and form a heterodimer with the regulatory subunit cyclin to perform its catalytic function.
  • the members of the CDKs family can be divided into periodic CDKs and transcriptional CDKs according to their functional differences.
  • the former mainly includes CDK1/2/4/6, which controls the cell cycle process; the latter mainly includes CDK7/8/9, which regulates the transcription of mRNA And processing (Malumbres M.et al. Genome Biol., 2014, 15:122).
  • CDK9 is related to the occurrence of a variety of tumors, inflammation, and virus replication, such as acute myeloid leukemia, breast cancer, colon cancer, and prostate cancer, as well as human immunodeficiency virus and adenovirus (Franco LCet al.J.Cell Biochem.,2017,119:1273-1284). These findings indicate that CDK9 is an effective target for cancer treatment.
  • CDK9 inhibitors that have entered the clinic include Flavopiridol, Dinaciclib, SNS-032 and CYC065, but they all lack the selectivity for CDK9.
  • CDK9 selective inhibitors currently in preclinical research such as LY2857785, LDC000067, BAY-1143572 and so on.
  • wogonin is isolated from wogonin. Both in vivo and in vitro pharmacological experiments have shown that wogonin has anti-inflammatory, anti-oxidant and anti-tumor activities and has low toxicity. It was discovered when the mechanism of its anti-tumor activity was studied.
  • Flavopiridol has a certain therapeutic effect on chronic lymphocytic leukemia, breast cancer, liver cancer and prostate cancer. It is now approved by the FDA as an orphan drug for the treatment of chronic lymphocytic leukemia, but Flavopiridol can easily cause side effects such as diarrhea.
  • Flavopiridol can easily cause side effects such as diarrhea.
  • the main purpose of the present invention is to find a class of CDK9 small molecule inhibitors containing benzofuran structure, high efficiency, low toxicity, and excellent drug metabolism properties, which can be used for disease prevention and/or treatment.
  • the present invention provides a compound represented by the general formula (I), and a pharmaceutically acceptable salt, ester, solvate or prodrug thereof.
  • R 1 is hydrogen
  • the R 2 is hydrogen, methyl or ethyl
  • the R 3 is methyl, ethyl, isopropyl
  • the Y is N, and the position of Y is the 3'or 4'position of the benzene ring;
  • the m is 1, 2 or 3;
  • the X is O, CR a or NR b ;
  • the Ra is hydrogen, hydroxyl or
  • the R b is hydrogen, methyl, ethyl, isopropyl
  • the compound of general formula (I) or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof according to the present invention is characterized in that the pharmaceutically acceptable salt refers to a compound of general formula I and a pharmaceutically acceptable
  • the salts formed by the acids include inorganic acid salts, the inorganic acids include: carbonic acid, hydrogen carbonate, sulfuric acid, hydrogen sulfate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, nitric acid, hydrogen chloride, hydrogen bromide, hydrogen Iodic acid, etc.; and organic acid salts, the organic acids include acetic acid, oxalic acid, lactic acid, succinic acid, tartaric acid, citric acid, methanesulfonic acid, pyruvic acid, benzenesulfonic acid, p-toluenesulfonic acid, ferulic acid, horse Acid, isobutyric acid, malonic acid, suberic acid, mandelic acid, fum
  • the compound of general formula (I) of the present invention or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof is used for the development of small molecule inhibitors targeting CDK9.
  • a pharmaceutical composition characterized in that the compound of the general formula (I) of the present invention or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof, and a pharmaceutically acceptable carrier.
  • Said pharmaceutical composition is characterized in that the compound of general formula (I) of the present invention or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof and pharmaceutically acceptable auxiliary materials.
  • Viruses include human immunodeficiency virus, cytomegalovirus, Epstein-Barr virus, adenovirus, herpes, human T cell lymphocyte virus, influenza A virus and dengue fever virus.
  • Tumors include nervous system cancer, blood cancer, liver cancer, muscle cancer, breast cancer, reproductive system cancer, lung cancer, gastrointestinal cancer, skin cancer, urinary system cancer and esophageal cancer.
  • the present invention aims at the disadvantages of low anti-tumor activity and poor druggability of wogonin.
  • the present invention transforms its core to synthesize a series of compounds, especially for the introduction of N-containing cyclic substituents at the 3'or 4'position, which contains nitrogen.
  • the introduction of cyclic substituents not only improves the selectivity of the compound to CDK9, but also improves the physical and chemical properties of the compound.
  • This type of compound is a brand-new compound, which has not been reported in the literature.
  • the inventor has made a series of activities against the synthesized compound. Specifically, most of the compounds of the present invention have better inhibitory activity on cancer cells. Compared with wogonin
  • the compounds with a great improvement and more prominent activity are mainly L26, L27, L32 and L38.
  • some compounds of the present invention have better inhibitory activity on CDK9, which is equivalent to Flavopiridol, but the selectivity to CDK9 is significantly improved.
  • the inhibitory activity of compound L26 on CDK9 is basically equivalent to that of Flicideidol, with an IC 50 value of 3.0 nM.
  • the selectivity of compound L32 for CDK9/CDK2 is 53 times that of wogon skullcap and 45 times that of Flicideidol.
  • some of the compounds of the present invention have better inhibitory activity on CDK9 and the selectivity for CDK9 is also better than Flchoidol.
  • Figure 2 The effect of compound L38 of the present invention on the expression of CDK9 and its downstream proteins and apoptotic proteins.
  • Example 2- The preparation of the compound described in Example 10 can be prepared by referring to the method and route described in Example 1.
  • Example 11 to Example 15 The preparation of the first seven-step intermediates of the compounds described in Example 11 to Example 15 can be obtained by referring to the method and route described in Example 1.
  • Example 12 For the preparation of the compounds described in Example 12 to Example 13, refer to the method and route described in Example 11.
  • Example 14 The preparation of the first nine intermediates of the compound described in Example 14 can be obtained by referring to the method and route described in Example 1 and Example 11.
  • Example 15 For the preparation of the first ten intermediates of the compound described in Example 15, refer to the method and route described in Example 1 and Example 11.
  • Example 16-Example 25 The preparation of the compound described in Example 16-Example 25 can be obtained by referring to the method and route described in Example 1.
  • Example 26 For the preparation of the compounds described in Example 26 to Example 27, refer to the method and route described in Example 1 and Example 11.
  • Example 28-Example 40 The preparation of the first four-step intermediates of the compound described in Example 28-Example 40 can be prepared by referring to the method and route described in Example 1.
  • Example 29-Example 40 The preparation of the compound described in Example 29-Example 40 can be prepared by referring to the method and route described in Example 28.
  • Cell culture materials DMEM liquid medium, 1640 liquid medium, 10% fetal bovine serum, 0.25% pancreatin, 1 ⁇ PBS
  • Inoculate cells digest the cells with 0.25% trypsin, and prepare a single cell suspension with cell culture medium containing 10% FBS. 4 ⁇ 10 3 ⁇ 10 4 cells per well were seeded in a 96-well culture plate with a volume of 100 ⁇ L per well.
  • Cultivation of cells Put the culture plate into a cell incubator at 37°C, 5% carbon dioxide and saturated humidity for 24 hours.
  • the drug can be administered: aspirate and discard the old culture medium in the culture plate, add the medium containing the drug, and continue to culture in the cell incubator for 72 hours.
  • the CDK9/cyclinT, CDK2/CyclinA complex was incubated with the substrate peptide 8mM MOPS, 0.2mM EDTA, 10mM magnesium acetate and 10 ⁇ M ⁇ -[ 33 P]-ATP. After adding the Mg-ATP mixture, react at room temperature for 40 minutes, and then add 3% phosphoric acid solution to stop the reaction. The reaction solution was spotted aliquot on the P30 filter pad, washed with 75mM phosphoric acid 3 times, 5min each time; washed with formaldehyde once. Then dry and count the scintillation.
  • MV4-11 cells in the logarithmic growth phase were seeded in a 6-well plate, the L26 compound was formulated into different concentration gradients and given to the cells, the cells were collected 24 hours later, washed once with PBS, and then added to apoptosis Staining solution, after 30 minutes, use a drain cytometer to detect.
  • compound L26 can induce apoptosis of MV4-11 cells in a concentration-dependent manner, and when the concentration of compound L26 is 1 ⁇ M, about 40% of cells can undergo apoptosis.
  • MV4-11 cells in the logarithmic growth phase were seeded in a 6-well plate, and different concentration gradients of compound L26 were given. After 4 hours, the cells were collected and the protein was extracted. DMSO was used as a negative control and ⁇ -actin was used as a negative control. Internal reference.
  • compound L26 can significantly reduce the expression of RNA polymerase II phosphorylated at Ser 2 by inhibiting the activity of CDK9, and can make the expression of the downstream short-apoptotic protein Mcl-1 concentration-dependent
  • the decrease in sex makes the expression of Cleaver caspase 3 increase in a concentration-dependent manner. This indicates that compound L26 increases the expression of downstream pro-apoptotic proteins by inhibiting the activity of CDK9, thereby causing cell apoptosis.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及到生物医药领域，具体包括苯并呋喃结构的新型CDK9抑制剂一系列衍生物和其用途；本发明针对汉黄芩素抗肿瘤活性低，成药性差的缺点，对其母核进行改造合成了一系列化合物，特别是针对3'或4'位引入含N环状取代基，该类化合物是全新化合物，未见文献报道，同时发明人针对合成的化合物进行了一系列生物活性评价，具体来说本发明大部分化合物对CDK9具有良好的选择性，并对癌细胞具有较好的抑制活性。

Description

[根据细则37.2由ISA制定的发明名称]　基于苯并吡喃结构的新型CDK9抑制剂、其制备方法及应用 技术领域
本发明涉及到生物医药领域，具体包括苯并呋喃结构的新型CDK9抑制剂一系列衍生物和其用途，具有涉及到作为CDK9抑制剂的化合物、上述化合物在药学上可接受的盐、酯、溶剂化物或前药，及上述化合物的药物组合物的用途。
技术背景
细胞周期蛋白依赖性激酶(Cyclin-dependent kinases，CDKs)是丝氨酸/苏氨酸激酶家族的一员，与调节亚基细胞周期蛋白形成异二聚体来发挥其催化功能。CDKs家族成员根据其功能的差异可以分为周期性CDKs和转录性CDKs，前者主要包括CDK1/2/4/6，控制细胞的周期进程；后者主要包括CDK7/8/9,调节mRNA的转录和加工(Malumbres M.et al.Genome Biol.,2014,15:122)。转录性CDKs的过表达或者功能增强会造成其下游特定基因的表达明显增加，特别是抗凋亡蛋白Mcl-1，从而引起肿瘤的发生(Morales F.et al.Cell Cycle,2016,15:519-27)。近年来发现非选择性的CDK抑制剂可以通过抑制CDK9的功能来达到抗肿瘤效应，因此对CDK抑制剂的研究也得到了人们的关注(Krystof V.et al.Target,Curr.Pharm.Des.,2012,18:2883–2890)。研究发现CDK9的过表达与多种肿瘤的发生、炎症的发生及病毒的复制有关，例如急性髓性白血病、乳腺癌、结肠癌和前列腺癌等及人类免疫缺陷病毒和腺病毒等(Franco L.C.et al.J.Cell Biochem.,2017,119:1273-1284)。这些发现表明了CDK9是治疗癌症的有效靶标。现在已经进入临床的CDK9抑制剂包括Flavopiridol、Dinaciclib、SNS-032和CYC065等，但都缺乏对CDK9的选择性。还有目前处于临床前研究的CDK9选择性抑制剂如LY2857785、LDC000067、BAY-1143572等。
目前研究较多的含苯并呋喃骨架的化合物主要有汉黄芩素和Flavopiridol。汉黄芩素是从汉黄芩中分离出来的，体内外药理学实验都表明汉黄芩素具有抗炎、抗氧化及抗肿瘤活性且毒性较低，在对其抗肿瘤活性的机制进行研究时发现其主要靶标是CDK9，并于2014年获得CFDA的临床批件，但汉黄芩素的抗肿瘤活性较弱(CDK9:IC 50＝198μM)并且其成药性较差。Flavopiridol是非选择性的CDK抑制剂，对CDK9有较强的抑制活性(IC 50＝20nM)。Flavopiridol对慢性淋巴细胞白血病、乳腺癌、肝癌及前列腺癌等多种癌症都具有一定的治疗作用，现在被FDA批准为治疗慢性淋巴细胞白血病的孤儿药，但Flavopiridol容易引起腹泻等副作用。为了进一步提高苯并呋喃类化合物对CDK9的选择性，改善其成药性，我们设计并合成了一系列含苯并呋喃类结构的CDK9小分子抑制剂。
发明内容
本发明的主要目的是寻找一类含苯并呋喃结构的，高效低毒且具有优良药物代谢性质的CDK9小分子抑制剂，用于疾病的预防和/或治疗。
本发明提供了通式(I)所示的化合物、其药学上可接受的盐、酯、溶剂化物或前药。
Figure PCTCN2020086917-appb-000001
Figure PCTCN2020086917-appb-000002
其中，所述R 1为氢、
Figure PCTCN2020086917-appb-000003
所述R 2为氢、甲基、乙基；
所述R 3为甲基、乙基、异丙基、
Figure PCTCN2020086917-appb-000004
Figure PCTCN2020086917-appb-000005
所述Y为N，Y的位置为所在苯环的3’位或者4’位；
所述m为1、2或者3；
所述X为O、CR a或者NR b；
所述R a为氢、羟基或者
Figure PCTCN2020086917-appb-000006
所述R b为氢、甲基、乙基、异丙基、
Figure PCTCN2020086917-appb-000007
Figure PCTCN2020086917-appb-000008
本发明所述的通式(I)化合物或其药学上可接受的盐、酯、溶剂化物或前药，其特征在于，药学上可接受的盐是指通式I的化合物和药学上可接受的酸形成的盐包括无机酸盐，所述的无机酸包括：碳酸、碳酸氢根、硫酸、硫酸氢根、磷酸、磷酸一氢根、磷酸二氢根、硝酸、氯化氢、溴化氢、氢碘酸等；以及有机酸盐，所述的有机酸包括乙酸、草酸、乳酸、琥珀酸、酒石酸、柠檬酸、甲磺酸、丙酮酸、苯磺酸、对甲苯磺酸、阿魏酸、马来酸、异丁酸、丙二酸、辛二酸、扁桃酸、反丁烯二酸等类似的酸；还包括与氨基酸形成的盐等。
本发明中所优选的部分化合物结构如下：
Figure PCTCN2020086917-appb-000009
Figure PCTCN2020086917-appb-000010
Figure PCTCN2020086917-appb-000011
Figure PCTCN2020086917-appb-000012
Figure PCTCN2020086917-appb-000013
Figure PCTCN2020086917-appb-000014
本发明所述的通式(I)化合物或其药学上可接受的盐、酯、溶剂化物或前药用于开发以CDK9为靶点的小分子抑制剂。
一种药物组合物，其特征在于，本发明所述的通式(I)化合物或其药学上可接受的盐、酯、溶剂化物或前药，和药学上可接受的载体。
所述的一种药物组合物，其特征在于，本发明所述的通式(I)化合物或其药学上可接受的盐、酯、溶剂化物或前药和药学上可接受的辅料。
本发明所述的通式(I)化合物或其药学上可接受的盐、酯、溶剂化物或前药，或一种药物组合物，在制备预防和治疗抗病毒药物和抗肿瘤药物中的用途。
本发明所述的通式(I)化合物或其药学上可接受的盐、酯、溶剂化物或前药在制备预防和治疗抗病毒药物和抗肿瘤药物中的用途，其特征在于，所述的病毒包括人类免疫缺陷病毒、巨细胞病毒、EB病毒、腺病毒、疱疹、人T细胞淋巴细胞病毒、甲型流感病毒和登革热病毒。
本发明所述的通式(I)化合物或其药学上可接受的盐、酯、溶剂化物或前药在制备预防和治疗抗病毒药物和抗肿瘤药物中的用途，其特征在于，所述的肿瘤包括神经系统癌症、血液癌症、肝癌、肌肉癌、乳腺癌、生殖系统癌症、肺癌、胃肠癌、皮肤癌、泌尿系统癌症和食管癌。
有益效果
本发明针对汉黄芩素抗肿瘤活性低，成药性差的缺点，本发明对其母核进行改造合 成了一系列的化合物，特别是针对3’或4’位引入含N环状取代基，含氮环状取代基的引入既提高了化合物对CDK9的选择性，同时改善了化合物的理化性质。该类化合物是全新化合物，未见文献报道，同时发明人针对合成的化合物做了一系列活性，具体来说本发明大部分化合物对癌细胞均有较好的抑制活性，相对于汉黄芩素有很大的提高，活性较为突出的化合物主要有L26、L27、L32和L38。
本发明部分化合物相对汉黄芩素对CDK9具有较好的抑制活性，与Flavopiridol相当，但对CDK9的选择性得到了明显的提高。特别是化合物L26对CDK9的抑制活性与Flavopiridol基本相当，其IC 50值达到了3.0nM，化合物L32对CDK9/CDK2的选择性是汉黄芩53倍，是Flavopiridol的45倍。
相对于CDK家族其他CDK来说，本发明部分化合物对CDK9具有较好的抑制活性且对CDK9的选择性也优于Flavopiridol。
本发明优选化合物L27的溶解度较好，特别是在酸性条件下(pH＝4.5)的溶解度相对于其他化合物得到了大幅度的提高在相同条件下其溶解度是汉黄芩素的500倍，Log D值也是处于合理的范围内。
选择活性较好化合物L26能通过抑制CDK9的活性，使得2位Ser磷酸化的RNA聚合酶II的表达量明显减少，并能使其下游的短促凋亡蛋白Mcl-1的表达量呈浓度依赖性的减少，使Cleaver caspase 3的表达量呈浓度依赖性的增加。这表明了化合物L26是通过抑制CDK9的活性，使得下游的促凋亡蛋白的表达增加，进而引起细胞发生凋亡的。
附图说明
图1本发明中化合物L38诱导MV4-11细胞凋亡实验结果；
图2本发明中化合物L38对CDK9及其下游蛋白及凋亡蛋白表达量的影响。
具体实施方式
下面通过具体的实施例对本发明做进一步的详细说明，但并不将本发明限制在所举的实施例范围之中。
实施例1
Figure PCTCN2020086917-appb-000015
第一步：中间体I-2的制备
将间苯三酚I-1(63g，0.5mol)加入到300mL无水乙醚中，室温搅拌溶解，再依次加入无水ZnCl 2(13.4g，0.1mol)和无水乙腈(50g，1.25mol)，0℃下通入干燥的HCl气体反应40h，TLC检测(V 石油醚：V 乙酸乙酯＝1:2)反应完全，静止待反应液温度升 至室温，抽滤，滤饼烘干至恒重后溶于200mL水中，加热回流6h，析出大量固体，冷却至室温，抽滤，烘干，得白色固体60g，收率71％。m.p.119～121℃。
第二步：中间体I-3的制备
将中间体I-2(33.6g，0.2mol)加入到350mL无水丙酮，室温搅拌溶解，再加入63.48g K 2CO 3(0.46mol)，室温条件下滴加硫酸二甲酯(39.78mL，0.42mol)，1h左右滴加完毕，45℃继续反应4h，TLC检测(V 石油醚：V 乙酸乙酯＝3:1)反应完全，静止冷却至室温，抽滤，滤液倒入5倍体积的水中，用1M HCl调pH＝3-4，析出大量固体。抽滤，干燥得白色固体32.5g，收率83％。m.p.80～82℃。
第三步：中间体I-4的制备
将中间体I-3(30g，15mmol)加入到450mL乙醇，室温搅拌溶解，再加入11.39g间溴苯甲醛(92mmol)，冰浴条件下滴加7％KOH水溶液280mL(0.21mol)，滴加过程中保持温度小于5℃。1h左右滴加完毕，40℃继续反应10h，TLC检测(V 石油醚：V 乙酸乙酯＝6:1)反应完全，静止冷却至室温，反应液倒入10倍体积的水中，用6M HCl调pH＝3-4，析出大量固体。抽滤，烘干，得黄色固体50.1g，收率90％。m.p.190～193℃。
第四步：中间体I-5的制备
中间体I-4(16.7g，46mmol)加入到43mL无水DMSO，升温至60℃，搅拌溶解，再加入催化量的I 2(0.36g，1.4mmol)，升温至130℃继续反应5h，TLC检测(V 石油醚：V 乙酸乙酯＝3:1)反应完全，反应液趁热倒入10倍体积的饱和硫代硫酸钠水溶液中，析出大量固体。抽滤，烘干，得淡黄色固体16.3g，收率97％。m.p.278～280℃。
第五步：中间体I-6的制备
将中间体I-5(20g，55mmol)加入到48％的氢溴酸300mL中，回流反应60h，TLC检测(V 石油醚：V 乙酸乙酯＝2:1)反应完全，静止冷却至室温，反应液倒入10倍体积的冰水中，析出大量固体。抽滤，滤饼用水多次洗涤至pH呈中性，干燥得粗品20.9g，聚酰胺柱层析(V 石油醚：V 乙酸乙酯＝2:1)得淡黄色固体15g，收率83％。m.p.192～196℃。
第六步：中间体I-7的制备
将中间体I-6(21g，64mmol)和氢氧化四甲铵(69g，38mmol)加入到450mL水中，室温搅拌溶解，再每隔20min分8次加入过硫酸钾(43g，169mmol)，加入过程中保持温度低于30℃，室温继续反应3h，TLC检测(V 石油醚：V 乙酸乙酯＝2:1)反应完全，抽滤，滤液用磷酸二氢钾(约30g)调pH＝6-7，析出固体，再每隔5min分3次加入45g氯化钠，室温搅拌过夜。抽滤，滤饼用20mL甲醇洗涤，烘干，得土黄色固体19g，收率60％。
第七步：中间体I-8的制备
将中间体I-7(7.8g，17.7mmol)加入到55mL DMF，室温搅拌溶解，再加入4.9g K 2CO 3(35.5mmol)，室温条件下滴加溴化苄(2.8mL，23mmol)，5min左右滴加完毕，60℃继续反应5h，TLC检测(V 二氯甲烷：V 甲醇＝10:1)反应完全，静止冷却至室温，抽滤，滤饼用20mL甲醇洗涤，滤液用6M HCl调pH＝1-2，室温搅拌过夜，析出固体。抽滤，滤饼用10mL甲醇洗涤，烘干，得橙黄色固体2.6g，收率38.8％。m.p.290～292℃。 1H NMR(300MHz,DMSO-d 6):δ＝12.69(s,1H,5-OH),9.13(s,1H,8-OH),7.92(d,2H,J＝9.00Hz,Ar-H),7.45(m,5H,Ar-H),7.12(d,2H,J＝9.00Hz,Ar-H),6.93(s,1H,CHCO),6.79(s,1H,Ar-H),5.34(s,2H,OCH 2-Ar)ppm.
第八步：中间体I-9的制备
将中间体I-8(720mg，1.9mmol)加入到60mL乙腈，室温搅拌溶解，再加入660mg K 2CO 3(4.8mmol)和240mg硫酸二甲酯(2.1mmol)，回流反应4.5h，TLC检测 (V 石油醚：V 乙酸乙酯＝2:1)反应完全，静止冷却至室温，抽滤，滤饼用20mL二氯甲烷洗涤，滤液减压蒸除溶剂，粗品用正己烷和二氯甲烷混合溶剂重结晶，得黄色固体685mg，收率92％。m.p.210～212℃。 1H NMR(300MHz,DMSO-d 6):δ＝12.70(s,1H,5-OH),7.93(d,2H,J＝9.00Hz,Ar-H),7.46(m,5H,Ar-H),7.10(d,2H,J＝9.00Hz,Ar-H),6.94(s,1H,CHCO),6.80(s,1H,Ar-H),5.33(s,2H,OCH 2-Ar),3.85(s,3H,ArOCH 3)ppm.
第九步：中间体I-10的制备
将中间体I-9(185mg,0.47mmol)加入到10mL无水DMSO，升温至60℃，搅拌溶解，再在N 2保护下依次加入410.7mg吗啉(4.8mmol)和121.9mg DIEA(0.94mmol)，90℃反应10h，TLC检测(V 石油醚：V 乙酸乙酯＝4:1)反应完全，反应液趁热倒入10mL饱和食盐水中，静止3h，抽滤，滤饼用10mL水洗涤，最终得到黄色固体178mg，产率74.9％。m.p.220～225℃. 1H NMR(300MHz,DMSO-d 6):δ＝12.79(s,1H,5-OH),7.86(d,2H,J＝9.00Hz,Ar-H),7.44(m,5H,Ar-H),6.97(d,2H,J＝9.00Hz,Ar-H),6.55(s,1H,CHCO),6.46(s,1H,Ar-H),5.23(s,2H,OCH 2-Ar),3.92(s,3H,ArOCH 3),3.30(s,4H,N(C H 2CH 2) 2NH),2.95(s,4H,N(CH 2C H 2) 2NH)ppm.
第十步：化合物L1的制备
将中间体I-10(185mg,0.27mml)和Pd/C(60mg)加入到10mL四氢呋喃和10mL甲醇，密闭体系通入氢气，35℃反应6h，TLC检测(V 乙酸乙酯：V 甲醇＝10:1)反应完全，静止冷却至室温，抽滤，滤液减压蒸除溶剂，硅胶柱层析(V 乙酸乙酯：V 甲醇＝15:1)最终得到黄色固体78mg，产率77％。m.p.204～206℃.HRMS(ESI),[M+H] +calculated for C20H19NO6 369.1212,found 369.1271. 1H NMR(300MHz,DMSO-d 6): ＝12.53(s,1H,5-OH),10.81(s,1H,7-OH),7.48(m,3H,Ar-H),7.20(d,1H,J＝7.50Hz,Ar-H),7.05(s,1H,CHCO),6.30(s,1H,Ar-H),3.85(s,3H,ArOCH3),3.77(s,4H,N(CH 2CH 2) 2O),3.23(s,4H,N(CH 2CH 2) 2O)ppm. 13C NMR(75MHz,DMSO-d 6): ＝182.1,163.4,157.3,156.2,151.5,149.6,131.6,129.8,127.6,118.7,116.7,112.2,105.0,103.7,99.0,66.0,61.0(2×C),48.0(2×C)ppm.IR(KBr)ν3245,2829,1657,1586,1507,1444,1356,1251,1163,1023,1010,863,837,699,671cm-1.
实施例2-实施例10所述化合物的制备，可参考实施例1中所描述的方法和路线制备得到。
实施例2：化合物L2
Figure PCTCN2020086917-appb-000016
m.p.150～153℃.HRMS(ESI),[M+H] +calculated for C 23H 26N 2O 5 410.1842,found 410.1907. 1H NMR(300MHz,DMSO-d 6):δ＝12.62(s,1H,5-OH),7.32(m,3H,Ar-H),6.95(d,1H,J＝6.0Hz,Ar-H),6.91(s,1H,CHCO),6.26(s,1H,Ar-H),4.45(m,1H,C H(CH 3) 2),3.60(s,4H,Ar-N(C H 2) 2),2.95(s,2H,NHC H 2),2.73(s,2H,NHC H 2),1.89(m,2H,NCH 2C H 2CH 2NH),1.28(d,6H,J＝6.00Hz,CH(C H 3) 2)ppm. 13C NMR(75MHz,DMSO-d 6):δ＝181.8,163.5,159.8,156.0,150.0,148.6,131.9,130.0,125.2,114.9,113.2,108.1,104.5,102.8,99.5,73.9,50.7,48.6,47.2,46.8,28.0,22.3(2×C)ppm.IR(KBr)ν 3445,2970,1652,1593,1497,1370,1322,1192,1109,1031,842,699,576,548cm -1.
实施例3：化合物L3
Figure PCTCN2020086917-appb-000017
m.p.240～242℃.HRMS(ESI),[M+H] +calculated for C 25H 28N 2O 5 436.1998,found 436.2065. 1HNMR(300MHz,DMSO-d 6):δ＝12.58(s,1H,5-OH),10.73(s,1H,7-OH),7.44(m,3H,Ar-H),7.18(d,1H,J＝7.2Hz,Ar-H),7.03(s,1H,CHCO),6.33(s,1H,Ar-H),4.83(m,1H,C H(CH 2) 4),3.25(s,4H,Ar-N(C H 2CH 2) 2N),2.50(s,4H,Ar-N(CH 2C H 2) 2N),2.26(s,3H,NCH 3),1.68(m,8H,CH(C H 2) 4)ppm. 13C NMR(75MHz,DMSO-d 6):δ＝182.1,163.4,157.8,155.8,151.4,150.0,131.5,129.8,125.4,118.8,116.6,112.4,104.9,103.7,99.1,84.0,54.4(2×C),47.7(2×C),45.6,32.3(2×C),23.2(2×C)ppm.IR(KBr)ν3441,2952,1651,1597,1496,1432,1375,1328,1260,1006,930,862,788,700,571cm -1.
实施例4：化合物L4
Figure PCTCN2020086917-appb-000018
m.p.190～195℃.HRMS(ESI),[M+H] +calculated for C 20H 20N 2O 5 368.1372,found 368.1439. 1HNMR(300MHz,DMSO-d 6):δ＝12.56(s,1H,5-OH),7.89(d,2H,J＝9.00Hz,Ar-H),7.14(d,2H,J＝9.00Hz,Ar-H),6.82(s,1H,CHCO),6.35(s,1H,Ar-H),3.98(s,3H,ArOCH 3),3.20(s,4H,N(C H 2CH 2) 2NH),2.90(s,4H,N(CH 2C H 2) 2NH)ppm. 13C NMR(75MHz,DMSO-d 6):δ＝182.1,163.3,158.5,156.2,151.8,149.6,127.8(2×C),118.8,116.3,113.3(2×C),104.8,103.1,99.3,60.8,48.6(2×C),45.2(2×C)ppm.IR(KBr)ν3537,2953,1643,1605,1575,1482,1443,1386,1215,1186,1124,992,837,670,553cm -1.
实施例5：化合物L5
Figure PCTCN2020086917-appb-000019
m.p.190～195℃.HRMS(ESI),[M+H] +calculated for C 21H 22N 2O 5 382.1529,found 382.1599. 1HNMR(300MHz,DMSO-d 6):δ＝12.70(s,1H,5-OH),10.91(s,1H,7-OH),7.82(d,2H,J＝9.00Hz,Ar-H),6.99(d,2H,J＝9.00Hz,Ar-H),6.57(s,1H,CHCO),6.43(s,1H,Ar-H),4.05(s,3H,ArOCH 3),3.44(s,4H,Ar-N(C H 2CH 2) 2N),3.01(s,3H,NCH 3),2.43(s,4H,Ar-N(CH 2C H 2) 2N)ppm. 13C NMR(75MHz,DMSO-d 6):δ＝182.3,167.8,157.5,156.1,150.9,149.6,127.3(2×C),118.5,116.4,113.0(2×C),105.1,103.7,99.1,61.0,52.1(2×C),45.5(2×C),42.2ppm.IR(KBr)ν3430,2854,2648,1653,1454,1367,1228,1210,1026,921,837,780,692,583cm -1.
实施例6：化合物L6
Figure PCTCN2020086917-appb-000020
m.p.207～210℃.HRMS(ESI),[M+H] +calculated for C 22H 24N 2O 6 412.1634,found 412.1701. 1HNMR(300MHz,DMSO-d 6):δ＝12.76(s,1H,5-OH),7.92(d,2H,J＝8.90Hz,Ar-H),7.10(d,2H,J＝8.90Hz,Ar-H),6.80(s,1H,CHCO),6.31(s,1H,Ar-H),3.88(s,3H,ArOCH 3),3.59(t,2H,J＝6.00Hz,NCH 2C H 2OH),3.37(s,4H,Ar-N(C H 2CH 2) 2N),2.60(s,4H,Ar-N(CH 2C H 2) 2N),2.49(t,2H,J＝6.00Hz,NC H 2CH 2OH)ppm. 13C NMR(75MHz,DMSO-d 6):δ＝181.7,163.6,157.0,156.2,153.1,149.3,127.7,127.5(2×C),118.9,114.0,113.9,103.4,101.8,98.9,60.9,60.1,58.5,52.8(2×C),46.6(2×C)ppm.IR(KBr)ν3380,2825,1656,1608,1580,1505,1392,1235,1207,1163,1102,1015,946,819,663cm -1.
实施例7：化合物L7
Figure PCTCN2020086917-appb-000021
m.p.210～213℃.HRMS(ESI),[M+H] +calculated for C 22H 24N 2O 5 396.1685,found 396.1710. 1HNMR(300MHz,DMSO-d 6):δ＝12.75(s,1H,5-OH),7.90(d,2H,J＝9.00Hz,Ar-H),7.08(d,2H,J＝9.00Hz,Ar-H),6.76(s,1H,CHCO),6.27(s,1H,Ar-H),4.38(m,1H,C H(CH 3) 2),3.28(s,4H,N(C H 2CH 2) 2NH),2.84(s,4H,N(CH 2C H 2) 2NH),1.30(d,6H,J＝6.09Hz,CH(C H 3) 2)ppm. 13C NMR(75MHz,DMSO-d 6):δ＝182.0,164.4,156.3,152.1,151.1,149.8,127.6(2×C),125.1,119.0,113.1(2×C),103.4,101.7,98.8,73.8,50.7(2×C),46.6(2×C),22.3(2×C)ppm.IR(KBr)ν3379,2813,1616,1525,1506,1368,1262,1237,1119,1026,821,663,595cm -1.
实施例8：化合物L8
Figure PCTCN2020086917-appb-000022
m.p.240～242℃.HRMS(ESI),[M+H] +calculated for C 23H 26N 2O 5 410.1842,found 410.1890. 1HNMR(300MHz,DMSO-d 6):δ＝12.76(s,1H,5-OH),10.59(s,1H,7-OH),7.92(d,2H,J＝9.00Hz,Ar-H),7.11(d,2H,J＝9.00Hz,Ar-H),6.79(s,1H,CHCO),6.28(s,1H,Ar-H),4.37(m,1H,C H(CH 3) 2),3.34(s,4H,Ar-N(C H 2CH 2) 2N),3.34(s,3H,NCH 3),2.45(s,4H,Ar-N(CH 2C H 2) 2N),1.30(d,6H,J＝6.09Hz,CH(C H 3) 2)ppm. 13C NMR(75MHz,DMSO-d 6):δ＝181.0,167.8,157.5,156.1,150.9,149.6,127.3(2×C),118.5,116.4,113.0(2×C),105.1,103.7,99.1,74.0,52.1(2×C),45.5(2×C),42.2,22.1(2×C)ppm.IR(KBr)ν3430,2854,2648,1653,1454,1367,1228,1210,1026,921,837,780,692,583cm -1.
实施例9：化合物L9
Figure PCTCN2020086917-appb-000023
m.p.265～268℃.HRMS(ESI),[M+H] +calculated for C 23H 24N 2O 6 424.1634,found 424.1707. 1HNMR(300MHz,DMSO-d 6):δ＝12.73(s,1H,5-OH),10.56(s,1H,7-OH),8.11(s,1H,NC HO),7.94(d,2H,J＝9.00Hz,Ar-H),7.15(d,2H,J＝9.00Hz,Ar-H),6.81(s,1H,CHCO),6.29(s,1H,Ar-H),4.38(m,1H,C H(CH 3) 2),3.52(s,4H,Ar-N(C H 2CH 2) 2N),3.40(m,4H,Ar-N(CH 2C H 2) 2N),1.30(d,6H,J＝6.15Hz,CH(C H 3) 2)ppm. 13C NMR(75MHz,DMSO-d 6):δ＝181.9,164.1,163.5,161.0,157.6,155.9,152.8,127.8,127.6(2×C),119.6,114.6(2×C),103.4,102.0,98.9,74.8,47.7,46.4,44.1(2×C),22.3(2×C)ppm.IR(KBr)ν3080,2972,1656,1574,1516,1433,1368,1277,1230,1202,1098,1003,968,847,825,658,559cm -1.
实施例10：化合物L10
Figure PCTCN2020086917-appb-000024
m.p.160～168℃.HRMS(ESI),[M+H] +calculated for C 26H 30N 2O 5 450.2188,found 450.2243. 1HNMR(300MHz,DMSO-d 6):δ＝12.90(s,1H,5-OH),7.88(d,2H,J＝9.00Hz,Ar-H),6.90(d,2H,J＝9.00Hz,Ar-H),6.72(s,1H,CHCO),6.30(s,1H,Ar-H),4.10(m,1H,C H(CH 2) 5),3.65(s,4H,Ar-N(C H 2) 2),3.00(s,2H,NHC H 2),2.83(s,2H,NHC H 2),1.90(m,2H,NCH 2C H 2CH 2NH),1.77(m,4H,CH(C H 2) 5),1.52(m,2H,CH(C H 2) 5),1.23(m,4H,CH(C H 2) 5)ppm. 13C NMR(75MHz,DMSO-d 6):δ＝181.5,163.6,158.6,155.3,153.6,149.5,127.8(2×C),125.1,118.8,113.3,111.4,109.0,103.6,98.9,81.0,60.1,50.9(2×C),47.2,46.9,33.9,27.8,26.3(2×C),23.9ppm.IR(KBr)ν3217,1654,1516,1400,1105,859,546cm -1.
实施例11-实施例15所述化合物的前七步中间体的制备，可参考实施例1中所描述的方法和路线制备得到。
实施例11：化合物L11
Figure PCTCN2020086917-appb-000025
第八步：中间体II-9的制备
将中间体I-7(6g，13.6mmol)加入到30mL DMF，室温搅拌溶解，再加入5.7g K 2CO 3(41mmol)，室温条件下滴加硫酸二甲酯(1.9g，15mmol)，5min左右滴加完毕，80℃继续反应10h，TLC检测(V 二氯甲烷：V 甲醇＝10:1)反应完全，静止冷却至室温，抽滤，滤饼用20mL甲醇洗涤，滤液用6M HCl调pH＝1-2，室温搅拌过夜，用300mL冰水稀释，析出大量固体。抽滤，滤饼烘干，粗品用甲醇和二氯甲烷的混合溶剂重结晶得黄色固1.0g，收率28％。m.p.155～158℃. 1H NMR(300MHz,DMSO-d 6):δ＝12.56(s,1H,5-OH),9.02(s,1H,8-OH),8.26(d,2H,J＝9.00Hz,Ar-H),7.46(d,2H,J＝9.00Hz,Ar-H),7.01(s,1H,CHCO),6.60(s,1H,Ar-H),3.96(s,3H,OCH 3)ppm.
第九步：中间体II-10的制备
将中间体II-9(3g，10mmol)加入到20mL DMF，室温搅拌溶解，再加入3.45g K 2CO 3(25mmol)和1.85g溴代异丙烷(15mmol)，80℃反应8h，TLC检测(V 石油 醚：V 乙酸乙酯＝1:1)反应完全，反应液趁热倒入10倍体积的冰水中，析出固体，静止2h，抽滤，烘干，粗品用乙醚和丙酮的混合溶剂重结晶，得黄色固体1.8g，收率52.3％。m.p.158～160℃. 1H NMR(300MHz,DMSO-d 6):δ＝12.59(s,1H,5-OH),8.15(d,2H,J＝9.00Hz,Ar-H),7.50(d,2H,J＝9.00Hz,Ar-H),7.02(s,1H,CHCO),6.62(s,1H,Ar-H),4.30(m,1H,C H(CH 3) 2),3.89(s,3H,OCH 3),1.36(d,6H,J＝6.00Hz,CH(C H 3) 2)ppm.
第十步：化合物L11的制备
将中间体II-10(100mg,0.29mmol)加入到10mL无水DMSO，升温至60℃，搅拌溶解，再在N 2保护下依次加入250mg哌嗪(2.90mmol)和375mg DIEA(2.90mmol)，80℃反应8h，TLC检测(V 石油醚：V 乙酸乙酯＝2:1)反应完全，反应液趁热倒入10mL饱和食盐水中，静止3h，抽滤，滤饼用10mL水洗涤，烘干得粗品90mg，粗品用甲醇和丙酮的混合溶剂重结晶，得黄色固体64mg，收率54％。m.p.190～192℃.HRMS(ESI),[M+H] +calculated for C 23H 26N 2O 5 411.1914,found 411.1917. 1H NMR(300MHz,DMSO-d 6):δ＝12.89(s,1H,5-OH),7.91(d,2H,J＝9.00Hz,Ar-H),7.07(d,2H,J＝9.00Hz,Ar-H),6.79(s,1H,CHCO),6.55(s,1H,Ar-H),4.32(m,1H,C H(CH 3) 2),3.90(s,3H,OCH 3),3.28(s,4H,N(C H 2CH 2) 2NH),2.82(s,4H,N(CH 2C H 2) 2NH),1.30(d,6H,J＝6.00Hz,CH(C H 3) 2)ppm. 13C NMR(75MHz,DMSO-d 6):δ＝181.9,164.0,158.6,156.4,153.6,149.1,127.7(2×C),126.0,118.5,113.8(2×C),103.8,101.5,95.8,75.2,56.4,47.7(2×C),45.3(2×C),22.4(2×C)ppm.IR(KBr)ν3350,2938,1650,1606,1580,1513,1380,1265,1204,1105,1069,1001,828,667,590cm -1.
实施例12-实施例13所述化合物的的制备，可参考实施例11中所描述的方法和路线制备得到。
实施例12：化合物L12
Figure PCTCN2020086917-appb-000026
m.p.160～168℃.HRMS(ESI),[M+H] +calculated for C 24H 28N 2O 5 425.2071,found 425.2074. 1H NMR(300MHz,DMSO-d 6):δ＝12.88(s,1H,5-OH),7.92(d,2H,J＝9.00Hz,Ar-H),7.10(d,2H,J＝9.00Hz,Ar-H),6.80(s,1H,CHCO),6.55(s,1H,Ar-H),4.32(m,1H,C H(CH 3) 2),3.89(s,3H,OCH 3),3.63(s,4H,N(C H 2CH 2) 2NH),3.35(s,4H,N(CH 2C H 2) 2NH),2.27(s,3H,NCH 3),1.29(d,6H,J＝6.00Hz,CH(C H 3) 2)ppm. 13C NMR(75MHz,DMSO-d 6):δ＝181.9,164.0,158.6,156.4,153.2,149.1,127.7(2×C),126.0,118.8,114.0(2×C),103.8,101.2,95.8,74.6,56.4,54.4(2×C),47.8(2×C),45.6,22.2(2×C)ppm.IR(KBr)ν3455,2971,2851,1654,1581,1519,1365,1323,1276,1253,1103,1006,944,850,806,591cm -1.
实施例13：化合物L13
Figure PCTCN2020086917-appb-000027
m.p.200～202℃.HRMS(ESI),[M+H] +calculated for C 24H 28N 2O 5 425.2071,found 425.2074. 1H NMR(300MHz,DMSO-d 6):δ＝13.04(s,1H,5-OH),7.87(d,2H,J＝9.00Hz,Ar-H),6.87(d,2H,J＝9.00Hz,Ar-H),6.72(s,1H,CHCO),6.53(s,1H,Ar-H),4.32(m,1H,C H(CH 3) 2),3.89(s,3H,OCH 3),3.63(s,4H,Ar-N(C H 2) 2),3.56(s,2H,NHC H 2),2.86(s,2H,NHC H 2),2.63(m,2H,NCH 2C H 2CH 2NH),1.29(d,6H,J＝6.00Hz,CH(C H 3) 2)ppm. 13C NMR(75MHz,DMSO-d 6):δ＝181.8,163.5,159.8,156.0,151.0,149.6,128.7(2×C),126.0,118.8,114.0(2×C),103.8,101.2,95.8,73.9,56.4,50.7,48.6,47.2,46.8,28.0,22.3(2×C)ppm.IR(KBr)ν3217,1654,1516,1400,1105,859,546cm -1.
实施例14所述化合物的前九步中间体的制备，可参考实施例1和实施例11中所描述的方法和路线制备得到。
实施例14：化合物L14
Figure PCTCN2020086917-appb-000028
第十步：中间体II-11的制备
中间体19(500mg，1.35mmol)和5mL DMF加入10mL耐压瓶中,室温搅拌溶解,微波反应(功率：300W)，升温至240℃反应30min。TLC检测(V 石油醚：V 乙酸乙酯＝2:1)反应完全，反应液倒入10mL冰水中，静止3h，析出固体，抽滤，滤饼烘干的黄色固体400mg，收率80％. 1HNMR(300MHz,DMSO-d 6):δ＝12.90(s,1H,5-OH),10.59(s,1H,7-OH),7.89(d,2H,J＝9.00Hz,Ar-H),7.21(d,2H,J＝9.00Hz,Ar-H),6.94(s,1H,CHCO),5.90(m,1H,-C H＝CH 2),5.43(m,2H,-CH＝C H 2),4.45(m,1H,C H(CH 3) 2),3.31(d,J＝5.70Hz,2H,-C H 2CH＝CH 2),1.29(d,6H,J＝6.00Hz,CH(C H 3) 2)ppm.
第十步：化合物L14的制备
将中间体II-11(100mg,0.27mmol)加入到8mL无水DMSO中，升温至60℃，搅拌溶解，再在N 2保护下依次加入116mg 4-甲基哌嗪(3.5mmol)和70mg DIEA(0.54mmol)，80℃反应24h，TLC检测(V 石油醚：V 乙酸乙酯＝2:1)反应完全，反应液趁热倒入10mL饱和食盐水中，静止3h，抽滤，滤饼用10mL水洗涤，烘干得粗品120mg，粗品用甲醇和二氯甲烷的混合溶剂重结晶，得黄色固体66mg，收率56％。m.p.203～208℃.HRMS(ESI),[M+H] +calculated for C 26H 30N 2O 5 451.2188,found 451.2263. 1HNMR(300MHz,DMSO-d 6):δ＝13.1(s,1H,5-OH),10.59(s,1H,7-OH),7.90(d,2H,J＝9.00Hz,Ar-H),6.89(d,2H,J＝9.00Hz,Ar-H),6.80(s,1H,CHCO),5.91(m,1H,-C H＝CH 2),4.96(m,2H,-CH＝C H 2),4.40(m,1H,C H(CH 3) 2),3.35(s,4H,N(C H 2CH 2) 2NH),3.31(d,J＝5.70Hz,2H,-C H 2CH＝CH 2),2.48(s,4H,N(CH 2C H 2) 2NH),2.25(s,3H,NCH 3),1.32(d,6H,J＝6.00Hz,CH(C H 3) 2)ppm. 13CNMR(75MHz,DMSO-d 6):δ＝181.6,163.2,158.3,155.5,153.7,151.1,147.6,135.8,127.5,124.4,118.9,116.4,114.5,113.9,111.4,109.2,101.8,75.2,51.8,51.3,49.3,48.7,46.6,27.7,22.1,21.8ppm.IR(KBr)ν3128,1647,1605,1582,1514,1480,1400,1224,1108,1007,823,546cm -1.
实施例15所述化合物的前十步中间体的制备，可参考实施例1和实施例11中所描述的方法和路线制备得到。
Figure PCTCN2020086917-appb-000029
实施例15：化合物L15
m.p.165～170℃.HRMS(ESI),[M+H] +calculated for C 26H 33N 3O 5468.2454,found468.2496. 1HNMR(300MHz,DMSO-d 6):δ＝13.5(s,1H,5-OH),7.86(d,2H,J＝9.00Hz,Ar-H),6.86(d,2H,J＝9.00Hz,Ar-H),6.60(s,1H,CHCO),4.46(m,1H,C H(CH 3) 2),3.87(s,2H,C H 2N(CH 3) 2),3.60(s,4H,Ar-N(C H 2) 2),2.82(s,2H,NHC H 2),2.77(s,2H,NHC H 2),2.56(s,6H,CH 2N(C H 3) 2),1.91(m,2H,NCH 2C H 2CH 2NH),1.27(d,6H,J＝6.00Hz,CH(C H 3) 2)ppm. 13CNMR(75MHz,DMSO-d 6):δ＝181.5,163.1,153.8,153.1,149.2,133.3,130.5,127.6,127.3,127.1,119.5,114.0,102.9,101.1,99.8,73.5,53.6,52.3,51.8,50.6,48.2,47.0,45.6,28.9,22.5,22.4ppm.IR(KBr)ν3126,1654,1577,1517,1400,1112,859,545cm -1.
实施例16-实施例25所述化合物的制备，可参考实施例1中所描述的方法和路线制备得到。
实施例16：化合物L16
Figure PCTCN2020086917-appb-000030
m.p.200～205℃. 1HNMR(300MHz,DMSO-d 6):δ＝12.75(s,1H,5-OH),7.92(d,2H,J＝9.00Hz,Ar-H),7.07(d,2H,J＝9.00Hz,Ar-H),6.76(s,1H,CHCO),6.30(s,1H,Ar-H),4.87(m,1H,OC H(CH 2) 2),3.42(m,4H,CHC H 2N&CHCH 2C H 2N),3.20(s,4H,N(C H 2CH 2) 2NH),3.07(s,4H,N(CH 2C H 2) 2NH),2.10(m,2H,CHC H 2CH 2N). 13C NMR(75MHz,DMSO-d 6):182.0,163.1,159.0,156.0,151.9,150.0,131.6,129.8,125.2,118.8,116.4,112.2,104.7,103.2,99.3,74.3,48.8(2×C),45.2(2×C),22.3(2×C)ppm.IR(KBr)ν3132,2970,1654,1603,1512,1073,547cm -1.
实施例17：化合物L17
Figure PCTCN2020086917-appb-000031
m.p.250～252℃.HRMS(ESI),[M+H] +calculated for C 26H 32N 3O 5466.2338,found466.2335. 1HNMR(300MHz,DMSO-d 6):δ＝12.70(s,1H,5-OH),7.77(d,2H,J＝9.00Hz,Ar-H),3.96(d,2H,J＝9.00Hz,Ar-H),6.52(s,1H,CHCO),6.28(s,1H,Ar-H),4.29(m,1H,Ar-OCH),3.38(s,4H,Ar-N(C H 2CH 2) 2N),2.97(s,4H,Ar-N(CH 2C H 2) 2N),2.59(t,2H,J＝6.00Hz,C H 2NCH 3),2.37(s,3H,NCH 3),2.09(s,3H,CH 2NC H 3),2.60(t,2H,J＝6.00Hz,C H 2NCH 3),1.76(m,4H,OCH(C H 2) 2)ppm. 13C NMR(75MHz,DMSO-d 6):δ＝182.28,163.82,157.90,157.49,153.27,149.77,127.58,124.75,120.52,114.46,104.48,103.04,99.46,77.24,54.69,52.63,47.30,46.11,45.45,30.75ppm.IR(KBr)ν3441,2952,1597, 1496,1432,1375,1328,1260,1006,930,862,788,699cm -1.
实施例18：化合物L18
m.p.190～195℃.HRMS(ESI),[M+H] +calculated for C 25H 24N 2O 6449.1707,found449.1702. 1HNMR(300MHz,DMSO-d 6):δ＝12.78(s,1H,5-OH),7.81(d,2H,J＝9.00Hz,Ar-H),7.34(s,1H,Ar-H),6.72(d,2H,J＝9.00Hz,Ar-H),6.64(s,1H,CHCO),6.38(s,1H,Ar-H),6.26(m,2H,Ar-H),4.98(s,2H,OCH 2-Ar),3.66(s,4H,Ar-N(C H 2) 2),3.07(s,2H,NHC H 2),2.86(s,2H,NHC H 2),1.95(m,2H,NCH 2C H 2CH 2NH)ppm. 13C NMR(75MHz,DMSO-d 6):δ＝181.98,163.60,157.56,156.24,153.42,151.76,148.70,143.74,127.74,124.60,119.72,112.76,110.66,107.52,104.36,101.39,99.30,66.82,58.02,49.24,48.44,47.12,28.96ppm.IR(KBr)ν3440,2927,1652,1598,1499,1368,1026,838,772,690,591cm -1.
实施例19：化合物L19
m.p.195～198℃.HRMS(ESI),[M+H] +calculated for C 24H 24N 4O 5449.1780,found449.1792. 1HNMR(300MHz,DMSO-d 6):δ＝12.80(s,1H,5-OH),11.88(s,1H,-NH-N＝),10.84(s,1H,7-OH),7.63(d,2H,J＝9.00Hz,Ar-H),7.00(d,2H,J＝9.00Hz,Ar-H),6.78(s,1H,CHCO),6.31(s,1H,Ar-H),3.41(s,4H,N(C H 2CH 2) 2NH),2.51(s,4H,N(CH 2C H 2) 2NH),2.00(s,6H,Ar-CH 3)ppm. 13C NMR(75MHz,DMSO-d 6):δ＝181.6,163.6,156.6,156.5,153.1,148.5,138.2,127.6(2×C),125.0,118.8,113.9(2×C),103.0,102.1,98.9,54.2(2×C),46.4(2×C),9.8ppm.IR(KBr)ν3407,1653,1587,1567,1514,1375,1222,1203,1107,1000,823,566,450cm -1.
实施例20：化合物L20
m.p.177～180℃.HRMS(ESI),[M+H] +calculated for C 25H 26N 4O 5463.1937,found 463.1972. 1HNMR(300MHz,DMSO-d 6):δ＝12.80(s,1H,5-OH),11.85(s,1H,-NH-N＝),7.63(d,2H,J＝9.00Hz,Ar-H),7.01(d,2H,J＝9.00Hz,Ar-H),6.78(s,1H,CHCO),6.33(s,1H,Ar-H),3.40(s,4H,Ar-N(C H 2CH 2) 2N),2.44(s,4H,Ar-N(CH 2C H 2) 2N),2.23(s,3H,NCH 3),1.98(s,6H,Ar-CH 3)ppm. 13C NMR(75MHz,DMSO-d 6):δ＝181.6,163.6,156.6,156.5,153.1,148.5,138.2,127.6(2×C),125.0,118.8,113.9(2×C),103.0,102.1,98.9,54.2(2×C),46.4(2×C),9.8(2×C)ppm.IR(KBr)ν3419,1654,1587,1567,1383,1236,1221,1106,1001,882,566,453cm -1.
实施例21：化合物L21
m.p.200～202℃.HRMS(ESI),[M+H] +calculated for C 23H 22N 4O 6451.1573,found 451.1596. 1HNMR(300MHz,DMSO-d 6):δ＝12.70(s,1H,5-OH),10.97(s,1H,7-OH),7.88(d,2H,J＝9.00Hz,Ar-H),7.07(d,2H,J＝9.00Hz,Ar-H),6.64(s,1H,CHCO),6.51(s,1H,Ar-H),5.94(s,1H,-NH-C H＝C),4.52(s,1H,-N H-CH＝C),3.33(s,4H,Ar-N(C H 2CH 2) 2N),2.44(s,4H,Ar-N(CH 2C H 2) 2N),2.22(s,3H,NCH 3)ppm. 13C NMR(75MHz,DMSO-d 6):182.1,165.9,163.6,159.0,150.3,147.7,131.0,128.8,127.3(2×C),121.7,111.7(2×C),104.5,103.7,99.0,57.2(2×C),52.0(2×C),46.6ppm.IR(KBr)ν3415,2972,1652,1587,1514,1379,1235,1203,1051,1004,827,664,559cm -1.
实施例22：化合物L22
m.p.178～180℃.HRMS(ESI),[M+H] +calculated for C 23H 22N 4O 5S 467.1344,found467.1362. 1HNMR(300MHz,DMSO-d 6):δ＝12.99(s,1H,5-OH),10.70(s,1H,7-OH),7.93(d,2H,J＝9.00Hz,Ar-H),7.12(d,2H,J＝9.00Hz,Ar-H),6.93(s,1H,CHCO),6.74(s,1H,Ar-H),6.61(m,3H,Ar-H&NH 2),3.44(s,4H,Ar-N(C H 2CH 2) 2N),2.59(s,4H, Ar-N(CH 2C H 2) 2N),2.32(s,3H,NCH 3)ppm. 13C NMR(75MHz,DMSO-d 6):182.1,168.9,163.6,161.8,160.8,152.7,137.7,130.5,126.9,127.3(2×C),111.7(2×C),108.0,104.5,104.0,99.3,57.2(2×C),52.0(2×C),46.6ppm.IR(KBr)ν3392,1655,1601,1512,1356,1209,1109,825,701,467cm -1.
实施例23：化合物L23
Figure PCTCN2020086917-appb-000032
m.p.164～168℃.HRMS(ESI),[M+H] +calculated for C 26H 28N 4O 6493.2042,found 493.2083. 1HNMR(300MHz,DMSO-d 6):δ＝12.80(s,1H,5-OH),11.92(s,1H,-NH-N＝),10.93(s,1H,7-OH),7.63(d,2H,J＝9.00Hz,Ar-H),7.00(d,2H,J＝9.00Hz,Ar-H),6.78(s,1H,CHCO),6.30(s,1H,Ar-H),4.50(s,1H,NCH 2CH 2O H),3.54(m,2H,NCH 2C H 2OH),3.33(s,4H,Ar-N(C H 2CH 2) 2N),2.55(s,4H,Ar-N(CH 2C H 2) 2N),2.44(t,2H,J＝6.00Hz,NC H 2CH 2OH),1.97(s,6H,Ar-CH 3)ppm. 13C NMR(75MHz,DMSO-d 6):181.6,163.7,156.6,156.5,153.1,148.5,138.0,127.6(2×C),125.0,118.7,113.7(2×C),103.0,101.9,98.9,60.1,58.5,52.8(2×C),48.6,46.5(2×C),10.1(2×C)ppm.IR(KBr)ν3412,2914,1654,1584,1513,1370,1223,1203,1106,1000,824,562cm -1.
实施例24：化合物L24
m.p.250～258℃.HRMS(ESI),[M+H] +calculated for C 29H 27N 5O 5 526.2012,found 526.2083. 1HNMR(300MHz,DMSO-d 6):δ＝12.80(s,1H,5-OH),11.91(s,1H,-NH-N＝),10.95(s,1H,7-OH),8.15(m,1H,Ar-H),7.66(d,2H,J＝9.00Hz,Ar-H),7.57(m,1H,Ar-H),7.06(d,2H,J＝9.00Hz,Ar-H),6.89(m,1H,Ar-H),6.80(s,1H,CHCO),6.68(m,1H,Ar-H),6.32(s,1H,Ar-H),3.66(s,4H,Ph-N(C H 2CH 2) 2N),3.48(s,4H,Ph-N(CH 2C H 2) 2N),1.99(s,6H,Ar-CH 3)ppm. 13C NMR(75MHz,DMSO-d 6):181.6,163.7,158.7,156.5(2×C),153.0,148.5,147.6,137.9,137.6,127.7(2×C),124.9,118.9,113.8,113.2,107.2,103.1,102.0,98.8,46.2(2×C),44.1(2×C),8.4(2×C)ppm.IR(KBr)ν3411,3167,2360,1652,1584,1563,1508,1434,1354,1227,1202,1103,998,953,844,818,773cm -1.
实施例25：化合物L25
m.p.200～202℃.HRMS(ESI),[M+H] +calculated for C 29H 26N 4O 7 543.1835,found 543.1861. 1HNMR(300MHz,DMSO-d 6):δ＝12.79(s,1H,5-OH),11.92(s,1H,-NH-N＝),10.96(s,1H,7-OH),7.88(s,1H,Ar-H),7.65(d,2H,J＝9.00Hz,Ar-H),7.04(m,3H,Ar-H),6.80(s,1H,CHCO),6.66(m,,1H,Ar-H),6.31(s,1H,Ar-H),3.82(s,4H,Ar-N(C H 2CH 2) 2N),3.47(s,4H,Ar-N(CH 2C H 2) 2N),1.98(s,6H,Ar-CH 3)ppm. 13C NMR(75MHz,DMSO-d 6):181.6,163.6,158.3,156.6,156.5,152.7,148.5,146.9,144.9,137.9,127.7(2×C),124.9,119.1,119.0,115.9,114.0,113.8,111.4,103.1,102.1,98.9,59.9(2×C),46.5(2×C),10.0(2×C)ppm.IR(KBr)ν3392,3163,2923,1581,1515,1433,1368,1279,1227,1103,1012,825,755,559cm -1.
实施例26-实施例27所述化合物的制备，可参考实施例1和实施例11中所描述的方法和路线制备得到。
实施例26：化合物L26
Figure PCTCN2020086917-appb-000033
m.p.200～203℃.HRMS(ESI),[M+H] +calculated for C 26H 28N 4O 5 477.2093,found 477.2124. 1HNMR(300MHz,DMSO-d 6):δ＝12.94(s,1H,5-OH),11.90(s,1H,-NH-N＝),7.72(d,2H,J＝8.60Hz,Ar-H),7.04(d,2H,J＝8.60Hz,Ar-H),6.86(s,1H,CHCO),6.61(s,1H,Ar-H),3.88(s,3H,ArOCH 3),3.40(s,4H,Ar-N(C H 2CH 2) 2N),2.60(s,4H,Ar-N(CH 2C H 2) 2N),2.35(s,3H,NCH 3),1.96(s,6H,Ar-CH 3)ppm. 13C NMR(75MHz,DMSO-d 6):182.3,172.5,164.4,158.2,157.5,148.3,138.3,137.0,128.7,128.2,126.1,123.5,114.5,104.0,102.5,96.4,57.1,54.2(2×C),46.4(2×C),9.1(2×C)ppm.IR(KBr)ν3425,2936,1656,1600,1514,1432,1375,1339,1223,1206,1126,999,816,661,567cm -1.
实施例27：化合物L27
Figure PCTCN2020086917-appb-000034
m.p.210～212℃.HRMS(ESI),[M+H] +calculated for C 25H 26N 4O 5 463.1937,found 463.1973. 1HNMR(300MHz,DMSO-d 6):δ＝12.94(s,1H,5-OH),11.89(s,1H,-NH-N＝),7.72(d,2H,J＝8.60Hz,Ar-H),7.02(d,2H,J＝8.60Hz,Ar-H),6.85(s,1H,CHCO),6.61(s,1H,Ar-H),3.88(s,3H,ArOCH 3),3.32(s,4H,Ar-N(C H 2CH 2) 2N),2.90(s,2H,Ar-N(CH 2C H 2) 2N),2.71(s,2H,Ar-N(CH 2C H 2) 2N),1.95(s,6H,Ar-CH 3)ppm. 13C NMR(75MHz,DMSO-d 6):181.8,163.8,157.7,157.0,147.8,137.8,127.9,127.7(2×C),125.6,118.9,114.0,103.5,102.0,95.9,56.5,46.1,45.5,45.4,44.1,9.5(2×C)ppm.IR(KBr)ν3410,2923,1655,1598,1513,1373,1224,1205,1124,999,825,567cm -1.
实施例28-实施例40所述化合物的前四步中间体的制备，可参考实施例1中所描述的方法和路线制备得到。
实施例28：化合物L28
Figure PCTCN2020086917-appb-000035
第五步：中间体VI-6的制备
将中间体I-5(15g，50mmol)加入到75mL无水DMF，冰浴至0℃，搅拌溶解，再加入NBS(8.93g，50mmol)，缓慢升温至室温继续反应2h，TLC检测(V 石油醚：V 乙酸乙酯＝1:2)反应完全，抽滤，滤饼用10mL甲醇洗涤。取出滤饼用20mL甲醇打浆，抽滤，滤饼干燥至恒重的白色固体15.36g，收率80％。
第六步：中间体VI-7的制备
将中间体VI-6(2g，4.26mmol)、吡咯烷(8.72mmol)、CsCO 3(2.84g，8.72mmol)、(Pd) 2(dba) 3(120mg，0.13mmol)和rac-BINAP(244mg，0.39mmol)加入50mL甲苯中，在N 2保护下回流36h。TLC检测(V 乙酸乙酯：V 二氯甲烷＝20:1)反应完全，缓慢冷却至室 温，减压蒸馏得到深棕色粘稠固体。固体用20ml二氯甲烷分散，用甲磺酸水溶液调至pH＝4-5，静置，分液得水层。水层用NaHCO3水溶液调至pH＝8-9，用20mL二氯甲烷萃取，二氯甲烷层用无水Na 2SO 4干燥，抽滤，滤液减压蒸馏得到黄棕色固体，干燥至恒重得黄棕色固体218mg，收率10.73％。
第七步：中间体VI-8的制备
将中间体VI-7(218mg，0.57mmol)溶于2mL二氯甲烷中，冰浴降至0℃以下。在N 2保护下加入三溴化硼(0.27mL，2.85mmol)，撤去冰浴，缓慢升至室温反应1h。TLC检测(V 二氯甲烷：V 甲醇＝15:1)反应完全。在冰浴条件下缓慢滴加10mL甲醇淬灭反应，减压蒸馏得棕色粗品。粗品用10mL二氯甲烷溶解，用NaHCO 3水溶液调至pH＝8-9，静置分液，二氯甲烷层用10mL饱和NaCl水溶液洗涤，无水Na 2SO 4干燥，抽滤，滤液减压蒸馏，得淡黄色固体183mg，收率86.8％；HRMS(ESI),[M+H] +calculated for C 20H 20FN 2O 4 371.1407,found 371.1397； 1HNMR(300MHz,DMSO-d 6)δ(ppm):8.23(q,J＝6.00Hz,2H,Ar-H),7.48(t,J＝9.00Hz,2H,Ar- H),7.03(s,1H,Ar-H),6.55(s,1H,Ar-H),3.91(s,3H,-OCH 3),3.02(m,8H,-CH 2-).
第八步：化合物L28的制备
将中间体VI-8(174mg，0.49mmol)，1-甲基哌嗪(490mg，4.9mmol),DIPEA(632mg，4.9mmol)溶于2mL DMSO中，升温至120-130℃反应1.5h。TLC检测(V 二氯甲烷：V 甲醇＝10:1)反应完全。冷却至室温，缓慢滴加10mL H 2O淬灭反应，用二氯甲烷萃取，二氯甲烷层用10mL饱和食盐水洗涤，无水Na 2SO 4干燥，抽滤，滤液减压蒸馏，过柱纯化的淡黄色固体163mg，收率73.9％；HRMS(ESI),[M+H] +calculated for C 25H 30N 3O 4436.2236,found 436.2243；76.5％； 1HNMR(300MHz,DMSO-d 6)δ(ppm):13.10(d,1H,Ar-OH),7.91(q,J＝6.00Hz,2H,Ar-H),7.08(t,J＝9.00Hz,2H,Ar-H),6.80(t,J＝12.00Hz,1H,Ar- H),6.44(d,J＝42.00Hz,1H,Ar-H),3.88(s,3H,-OCH 3),3.35(m,8H,-N-CH 2-),3.21(s,2H,-CH 2-),2.50(d,4H,-CH 2-),2.25(s,3H,-CH 3),1.97(s,2H,-CH 2-).
实施例29-实施例40所述化合物的制备，可参考实施例28中所描述的方法和路线制备得到。
实施例29：化合物L29
Figure PCTCN2020086917-appb-000036
HRMS(ESI),[M+H] +calculated for C 25H 30N 3O 5 452.2185,found 452.2196； 1H NMR(300MHz,chloroform-d)δ(ppm):13.02(s,1H,Ar-OH),7.93(d,J＝6.00Hz,2H,Ar-H),7.03(d,J＝9.00Hz,2H,Ar-H),6.58(s,1H,Ar-H),6.40(s,1H,Ar-H),3.92(s,3H,O-CH 3),3.89(t,J＝3.00Hz,4H,-O-CH 2-),3.50(t,J＝6.00Hz,4H,-N-CH 2-),3.20(t,J＝9.00Hz,4H,-N-CH 2-),2.70(t,J＝6.00Hz,4H,-N-CH 2-),2.47(s,3H,-CH 3).
实施例30：化合物L30
Figure PCTCN2020086917-appb-000037
HRMS(ESI),[M+H] +calculated for C 25H 28N 5O 4 462.2141,found 462.2158； 1HNMR(300MHz,DMSO-d 6)δ(ppm):7.53(d,J＝9.00Hz,2H,Ar-H),7.35(s,1H,N-CH＝),6.90(d,J＝9.00Hz,2H,Ar- H),6.69(s,1H,Ar- H),6.54(s,1H,-C-C H＝),5.48(d,J＝3.00Hz,1H,Ar- H),3.85(s,3H,-N-CH 3),3.53(s,3H,-OCH 3),3.29(m,4H,-CH 2-),2.51(m,4H,-CH 2-),2.21(s,3H,-CH 3).
实施例31：化合物L31
Figure PCTCN2020086917-appb-000038
HRMS(ESI),[M+H] +calculated for C 26H 32N 3O 4 450.2393,found 450.2392； 1H NMR(300MHz,MeOH-d)δ(ppm):7.85(d,J＝9.00Hz,2H,Ar-H),6.98(d,J＝9.00Hz,2H,Ar-H),6.47(s,1H,Ar-H),6.36(s,1H,Ar-H),3.85(s,3H,-OCH 3),3.32(s,4H,-N-CH 2-),3.25(d,J＝3.00Hz,4H,-N-CH 2-),3.00(s,4H,-N-CH 2-),2.54(d,J＝3.00Hz,4H,-N-CH 2-),2.30(s,3H,-NCH 3).
实施例32：化合物L32
Figure PCTCN2020086917-appb-000039
HRMS(ESI),[M+H] +calculated for C 25H 31N 4O 4 451.2345,found 451.2330； 1H NMR(300MHz,chloroform-d)δ(ppm):12.99(s,1H,Ar-OH),7.94(d,J＝9.00Hz,2H,Ar-H),7.02(d,J＝9.00Hz,2H,Ar-H),6.95(s,1H,Ar-H),6.37(s,1H,Ar-H),3.90(s,3H,-OCH 3),3.45(s,4H,-N-CH 2-),3.10(s,4H,-N-CH 2-),2.66(s,4H,-N-CH 2-),2.43(s,3H,-N-CH 3),1.71(m,6H,-CH 2-).
实施例34：化合物L34
Figure PCTCN2020086917-appb-000040
HRMS(ESI),[M+H] +calculated for C 21H 21FNO 5 386.1404,found 386.1418； 1HNMR(300MHz,DMSO-d 6)δ(ppm):12.88(s,1H,Ar-OH),8.21(q,J＝6.00Hz,2H,Ar-H),7.49(t,J＝9.00Hz,2H,Ar- H),7.02(s,1H,Ar-H),6.55(s,1H,Ar-H),4.67(s,1H,-C-OH),3.90(s,3H,-OCH 3),3.71(m,1H,-CH-),2.92(m,4H,-CH 2-),1.71(m,4H,-CH 2-).
实施例35：化合物L35
Figure PCTCN2020086917-appb-000041
HRMS(ESI),[M+H] +calculated for C 22H 24FN 2O 4 399.1720,found 399.1731； 1HNMR(300MHz,chloroform-d)δ(ppm):12.80(s,1H,Ar-OH),8.02(t,J＝6.00Hz,2H,Ar-H),7.25(d,J＝9.00Hz,2H,Ar- H),6.63(s,1H,Ar-H),6.40(s,1H,Ar-H),3.91(s,3H,-OCH 3),3.05(m,4H,-CH 2-),2.85(m,2H,-CH-),1.12(d,J＝6.00Hz,6H,-CH 3),0.89(d,J＝9.00Hz,1H,-NH-).
实施例36：化合物L36
Figure PCTCN2020086917-appb-000042
HRMS(ESI),[M+H] +calculated for C 23H 24FN 2O 7S 491.1288,found 491.1293； 1HNMR(300MHz,chloroform-d)δ(ppm):12.87(s,1H,Ar-OH),7.94(d,J＝6.00Hz,2H,Ar-H),7.34(d,J＝9.00Hz,2H,Ar- H),6.65(s,1H,Ar-H),6.43(s,1H,Ar-H),4.19(m,2H,-OC H 2CH 3),3.96(s,3H,-OCH 3),3.50(m,8H,-CH 2-),1.37(t,J＝9.00Hz,3H,-CH 3).
实施例37：化合物L37
Figure PCTCN2020086917-appb-000043
HRMS(ESI),[M+H] +calculated for C 20H 20FN 2O 5S 419.1077,found 419.1091； 1HNMR(300MHz,chloroform-d)δ(ppm):12.85(s,1H,Ar-OH),7.97(q,J＝3.00Hz,2H,Ar-H),7.29(d,J＝18.00Hz,2H,Ar- H),6.64(s,1H,Ar-H),6.43(s,1H,Ar-H),3.95(s,3H,-OCH 3),3.65(t,J＝9.00Hz,4H,-CH 2-),3.28(d,J＝6.00Hz,4H,-CH 2-).
实施例38：化合物L38
Figure PCTCN2020086917-appb-000044
HRMS(ESI),[M+H] +calculated for C 24H 29N 4O 4 437.2189,found 437.2154； 1H NMR(300MHz,DMSO-d 6)δ(ppm):7.96(d,J＝12.00Hz,2H,Ar-H),7.08(d,J＝9.00Hz,2H, Ar-H),6.72(s,1H,Ar-H),6.47(s,1H,Ar-H),3.88(s,3H,-OCH 3),3.75(s,8H,-CH 2-),3.86(d,J＝18.00Hz,8H,-CH 2-).
实施例39：化合物L39
Figure PCTCN2020086917-appb-000045
HRMS(ESI),[M+H] +calculated for C 24H 28N 3O 5 438.2029,found 438.2041； 1H NMR(300MHz,DMSO-d 6)δ(ppm):8.00(d,J＝12.00Hz,2H,Ar-H),7.09(t,J＝6.00Hz,2H,Ar-H),6.77(s,1H,Ar-H),6.48(s,1H,Ar-H),3.87(s,3H,-OCH 3),3.74(m,4H,-O-CH 2-),3.03(t,J＝6.00Hz,4H,-N-CH 2-),2.86(t,J＝3.00Hz,4H,-N-CH 2-),2.51(s,4H,-N-CH 2-).
实施例40：化合物L40
Figure PCTCN2020086917-appb-000046
1H NMR(300MHz,DMSO-d 6)δ(ppm):8.00(d,J＝9.00Hz,2H,Ar-H),7.00(d,J＝9.00Hz,3H,Ar-H),6.79(s,1H,Ar-H),6.49(s,1H,Ar-H),3.89(s,3H,-OCH 3),3.55(t,J＝6.00Hz,5H,-N-CH 2-),3.00(m,4H,-N-CH 2-),2.90(q,J＝6.00Hz,8H,-CH 2-),2.48(q,J＝6.00Hz,4H,-CH 2-),1.85(d,J＝12.00Hz,2H,-CH 2-),1.45(m,2H,-CH 2-).
下面是此发明部分化合物的生物药理学实验和结果：
一、本发明部分化合物对癌细胞的生长抑制活性
实验材料：
a.MTT溶液的配置
将250mg MTT，加入到50mL灭菌后的1×PBS(0.01mol/L pH＝7.4)中，避光搅拌30min，用0.22μm的微孔滤膜过滤，然后分装于EP管中，-20℃避光保存。
b.细胞培养:
细胞株：HepG2、A549、HCT116和THP-1
细胞培养材料：DMEM液体培养基，1640液体培养基,10％胎牛血清，0.25％胰酶，1×PBS
c.其他：
分析纯DMSO溶液，细胞计数板，96孔细胞培养板
实验仪器：
酶联免疫检测仪
实验步骤：
(1)铺板
接种细胞：用0.25％胰酶将细胞消化，用含10％FBS的细胞培养基配成单个细胞悬液。以每孔4×10 3～10 4个细胞接种于96孔培养板中，每孔体积100μL。
培养细胞：将培养板放入细胞培养箱，37℃、5％二氧化碳及饱和湿度条件下，培养24小时。
(2)加药
显微镜下观察细胞已贴壁且呈正常生长形态，即可进行给药：吸弃培养板中的旧培养液，加入含药物的培养液继续在细胞培养箱内培养72h。
(3)呈色
培养72h后，每孔加入20μLMTT溶液(5mg/mL)，37℃继续孵育4h，去除上清液，每孔加入150μL DMSO，震荡10min，使甲瓒充分溶解。
(4)比色
492nm波长，在酶联免疫检测仪上测定各孔光吸收值，记录实验结果。
(5)实验结果分析
实验结果如下表所示。
表1 本发明部分化合物对癌细胞的生长抑制活性
Figure PCTCN2020086917-appb-000047
Figure PCTCN2020086917-appb-000048
由表1可见，本发明大部分化合物对癌细胞均有较好的抑制活性，相对于汉黄芩素有很大的提高，活性较为突出的化合物主要有L26、L27、L32和L38。
二、本发明部分化合物对激酶CDK9和CDK2的抑制活性
实验原理和实验方法：
CDK9/cyclinT、CDK2/CyclinA复合物与底物肽8mM MOPS、0.2mM EDTA、10mM醋酸镁和10μΜγ-[ 33P]-ATP一起孵育。加入Mg-ATP混合物后，室温反应40分钟，加入3％磷酸溶液中止反应。将反应液等分点样到P30滤垫上，用75mM磷酸洗涤3次，每次5min；用甲醛洗涤1次。然后干燥并闪烁计数。通过在不同浓度的化合物存在的情况下，在60mM的HEPES-氢氧化钠(pH 7.5)中3mM的氯化镁，3mM的氯化锰，3μM的钠-原钒，1.2mM DTT，50μg/mL PEG20000和1μM的ATP中将CDK9-cyclin T、CDK2-Cyclin A复合物与重组底物RBERCHK tide在30℃条件下孵育2h。通过使用磷酸化特异性抗体和western blot分析检测磷酸化底物。
实验结果如下表所示。
表2 本发明部分化合物对激酶CDK9和CDK2的IC 50值
Figure PCTCN2020086917-appb-000049
Figure PCTCN2020086917-appb-000050
NA表示化合物对CDK2没有抑制活性。
由表2可见，本发明部分化合物相对汉黄芩素对CDK9具有较好的抑制活性，与Flavopiridol相当，但对CDK9的选择性得到了明显的提高。特别是化合物L26对CDK9的抑制活性与Flavopiridol基本相当，其IC 50值达到了3.0nM，化合物L32对CDK9/CDK2的选择性是汉黄芩53倍，是Flavopiridol的45倍。
三、本发明部分化合物对不同CDKs的选择性
表3 本发明部分化合物对不同CDKs的选择性
Figure PCTCN2020086917-appb-000051
由表3可见，相对于CDK家族其他激酶，本发明部分化合物对CDK9具有较好的抑制活性且对CDK9的选择性也优于汉黄芩素以及临床II期药物Flavopiridol。
四、本发明部分化合物的类药性参数
表4 本发明部分化合物的类药性参数
Figure PCTCN2020086917-appb-000052
由表4可见，本发明优选化合物L27的溶解度较好，特别是在酸性条件下(pH＝4.5)的溶解度相对于其他化合物得到了大幅度的提高在相同条件下其溶解度是汉黄芩素的500倍，Log D值也是处于合理的范围内。
五、我们选取了活性较好的化合物L26，对其进行了诱导MV4-11细胞凋亡的实验。
实验方法：将处于对数生长期的MV4-11细胞接种于6孔板内，将L26化合物配制成不同的浓度梯度并给与细胞，24小时后收集细胞，PBS洗涤一次，然后加入细胞凋亡染色液，30分钟后用流失细胞仪进行检测。
结果如下：
图1本发明中化合物L26诱导MV4-11细胞凋亡实验结果
由图1可见，化合物L26能够以浓度依赖性的方式诱导MV4-11细胞凋亡，当化合物L26的浓度为1μM时可以使约40％的细胞发生凋亡。
六、我们用WB的方法对化合物L26的抗肿瘤作用机制进行了研究，我们考察了化合物L26对CDK9及其下游蛋白表达量的影响。
实验方法：将处于对数生长期的MV4-11细胞接种于6孔板内，并给与不同浓度梯 度的化合物L26,4小时后收集细胞，提取蛋白，以DMSO作为阴性对照，β-actin作为内参。
结果如下：
由图2可见，化合物L26能通过抑制CDK9的活性，使得2位Ser磷酸化的RNA聚合酶II的表达量明显减少，并能使其下游的短促凋亡蛋白Mcl-1的表达量呈浓度依赖性的减少，使Cleaver caspase 3的表达量呈浓度依赖性的增加。这表明了化合物L26是通过抑制CDK9的活性，使得下游的促凋亡蛋白的表达增加，进而引起细胞发生凋亡的。

Claims (8)

  1. 一种如通式(I)所示的化合物、其药学上可接受的盐、酯、溶剂化物或前药
    Figure PCTCN2020086917-appb-100001
    其中，所述R 1为氢、
    Figure PCTCN2020086917-appb-100002
    所述R 2为氢、甲基或乙基；
    所述R 3为甲基、乙基、异丙基、
    Figure PCTCN2020086917-appb-100003
    Figure PCTCN2020086917-appb-100004
    所述Y为N，Y的位置为所在苯环的3’位或4’位；
    所述m为1、2或者3；
    所述X为O、CR a或NR b；
    所述R a为氢、羟基或
    Figure PCTCN2020086917-appb-100005
    所述R b为氢、甲基、乙基、异丙基、
    Figure PCTCN2020086917-appb-100006
    Figure PCTCN2020086917-appb-100007
  2. 根据权利要求1所述的化合物，其特征在于药学上可接受的盐是指通式(I)的化合物和药学上可接受的酸形成的盐，包括无机酸盐和有机酸盐；其中所述的无机酸包括： 碳酸、碳酸氢根、硫酸、硫酸氢根、磷酸、磷酸一氢根、磷酸二氢根、硝酸、氯化氢、溴化氢或氢碘酸；所述的有机酸包括乙酸、草酸、乳酸、琥珀酸、酒石酸、柠檬酸、甲磺酸、丙酮酸、苯磺酸、对甲苯磺酸、阿魏酸、马来酸、异丁酸、丙二酸、辛二酸、扁桃酸、反丁烯二酸或氨基酸。
  3. 根据权利要求1或2所述的化合物，其特征在于：所述的化合物为如下结构任意一项：
    Figure PCTCN2020086917-appb-100008
    Figure PCTCN2020086917-appb-100009
    Figure PCTCN2020086917-appb-100010
    Figure PCTCN2020086917-appb-100011
    Figure PCTCN2020086917-appb-100012
  4. 一种药物组合物，其特征在于，权利要求1-3任意一种化合物或其药学上可接受的盐、酯、溶剂化物或前药，和药学上可接受的辅料。
  5. 根据权利要求1-4任意一项所述的化合物在制备以CDK9为靶点的小分子抑制剂药物中的应用。
  6. 根据权利要求1-4任意一项所述的化合物在制备预防或治疗抗病毒药物和抗肿瘤药物中的应用。
  7. 根据权利要求6所述的应用，其特征在于：所述的病毒包括HIV病毒、巨细胞病毒、EB病毒、腺病毒、疱疹、人T细胞淋巴细胞病毒、甲型流感病毒和登革热病毒。
  8. 根据权利要求6所述的应用，其特征在于：所述的肿瘤包括神经胶质瘤、白血病、淋巴癌、肝癌、肌肉癌、乳腺癌、前列腺癌、肺癌、胃肠癌、皮肤癌、卵巢癌和食管癌。
PCT/CN2020/086917 2019-05-13 2020-04-26 基于苯并吡喃结构的新型cdk9抑制剂、其制备方法及应用 Ceased WO2020228513A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910392404.2A CN110028475B (zh) 2019-05-13 2019-05-13 基于苯并吡喃结构的新型cdk9抑制剂、其制备方法及应用
CN201910392404.2 2019-05-13

Publications (1)

Publication Number Publication Date
WO2020228513A1 true WO2020228513A1 (zh) 2020-11-19

Family

ID=67241917

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/086917 Ceased WO2020228513A1 (zh) 2019-05-13 2020-04-26 基于苯并吡喃结构的新型cdk9抑制剂、其制备方法及应用

Country Status (2)

Country Link
CN (1) CN110028475B (zh)
WO (1) WO2020228513A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022167697A1 (en) * 2021-02-08 2022-08-11 Floratek Pharma SA Heteroaromatic spermidine analogues and their anticancer activity
WO2022200540A1 (en) * 2021-03-24 2022-09-29 Floratek Pharma SA Hetero benzyl amines and their use treating central nervous system disorders
CN116041302A (zh) * 2022-12-02 2023-05-02 泉州海创医药科技有限公司 制备含羟基取代基的黄酮类化合物的方法
CN116925055A (zh) * 2023-07-19 2023-10-24 宁夏大学 香豆素-哌嗪-呋喃酮杂化物及其制备方法和应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110028475B (zh) * 2019-05-13 2022-07-01 中国药科大学 基于苯并吡喃结构的新型cdk9抑制剂、其制备方法及应用
CN112870363B (zh) * 2021-04-03 2022-02-18 兰州大学第一医院 人pcid2蛋白在制备或筛选抗肿瘤药物中的应用及具有抗肿瘤活性的化合物
CN113603708B (zh) * 2021-07-27 2023-08-11 中国药科大学 一种具有大环骨架结构的cdk9抑制剂的制备及其应用
CN114957182B (zh) * 2022-03-30 2024-03-15 中国药科大学 一类含有黄酮骨架结构的usp8抑制剂及其应用
CN115160279B (zh) * 2022-07-27 2023-11-24 中国药科大学 苯并吡喃酮类化合物、药物组合物和应用
CN117304156A (zh) * 2023-09-26 2023-12-29 上海上药第一生化药业有限公司 一种二甲弗林类似物及其精制方法
CN117304154A (zh) * 2023-09-26 2023-12-29 上海上药第一生化药业有限公司 一种二甲弗林类似物的制备方法
CN119564666B (zh) * 2025-02-06 2025-04-25 杭州师范大学 异去氢淫羊藿素在制备抗ⅰ型单纯疱疹病毒药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366061A1 (de) * 1988-10-28 1990-05-02 Hoechst Aktiengesellschaft Die Verwendung von 4H-1-Benzopyran-4-on-Derivaten, neue 4H-1-Benzopyran-4-on-Derivate und diese enthaltende Arzneimittel
CN1668613A (zh) * 2002-07-08 2005-09-14 尼古拉斯·皮拉马尔印度有限公司 作为细胞周期蛋白依赖型激酶抑制剂的黄酮衍生物
CN101472888A (zh) * 2006-06-21 2009-07-01 皮拉玛生命科学有限公司 用于治疗增殖性病变的光学纯的黄酮衍生物及其制备方法
CN110028475A (zh) * 2019-05-13 2019-07-19 中国药科大学 基于苯并呋喃结构的新型cdk9抑制剂、其制备方法及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810552B (zh) * 2017-01-20 2019-05-07 中国药科大学 硫代乙内酰脲三元并环类雄激素受体拮抗剂及其用途
CN108148053B (zh) * 2017-12-22 2021-06-04 郑州大学 磺胺三氮唑类Tubulin聚合抑制剂及其合成方法和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366061A1 (de) * 1988-10-28 1990-05-02 Hoechst Aktiengesellschaft Die Verwendung von 4H-1-Benzopyran-4-on-Derivaten, neue 4H-1-Benzopyran-4-on-Derivate und diese enthaltende Arzneimittel
CN1668613A (zh) * 2002-07-08 2005-09-14 尼古拉斯·皮拉马尔印度有限公司 作为细胞周期蛋白依赖型激酶抑制剂的黄酮衍生物
CN101472888A (zh) * 2006-06-21 2009-07-01 皮拉玛生命科学有限公司 用于治疗增殖性病变的光学纯的黄酮衍生物及其制备方法
CN110028475A (zh) * 2019-05-13 2019-07-19 中国药科大学 基于苯并呋喃结构的新型cdk9抑制剂、其制备方法及应用

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022167697A1 (en) * 2021-02-08 2022-08-11 Floratek Pharma SA Heteroaromatic spermidine analogues and their anticancer activity
WO2022167698A1 (en) * 2021-02-08 2022-08-11 Floratek Pharma SA Heteroaromatic spermidine analogues and their anticancer activity
WO2022167699A1 (en) * 2021-02-08 2022-08-11 Floratek Pharma SA Heteroaromatic spermidine analogues and their anticancer activity
WO2022167696A1 (en) * 2021-02-08 2022-08-11 Floratek Pharma SA Flavone deaza spermidine analogues and their use treating cancer
WO2022200540A1 (en) * 2021-03-24 2022-09-29 Floratek Pharma SA Hetero benzyl amines and their use treating central nervous system disorders
CN116041302A (zh) * 2022-12-02 2023-05-02 泉州海创医药科技有限公司 制备含羟基取代基的黄酮类化合物的方法
CN116925055A (zh) * 2023-07-19 2023-10-24 宁夏大学 香豆素-哌嗪-呋喃酮杂化物及其制备方法和应用

Also Published As

Publication number Publication date
CN110028475A (zh) 2019-07-19
CN110028475B (zh) 2022-07-01

Similar Documents

Publication Publication Date Title
WO2020228513A1 (zh) 基于苯并吡喃结构的新型cdk9抑制剂、其制备方法及应用
CN109134448B (zh) 杂环化合物及其盐、制备方法、用途和药物
CN103848747B (zh) 姜黄素类似物、其药用盐及其制备和应用
CN110016021B (zh) 一种免疫调节剂
CN106496233B (zh) 吡咯并嘧啶类化合物、其制备方法及其用途
WO2020228635A1 (zh) 一种egfr激酶抑制剂及其在制备抗癌药物方面的应用
CN106831725B (zh) 含二氢吲哚啉及类似结构的喹唑啉类化合物及其应用
CN107400093A (zh) 2,4‑二苯胺基嘧啶类化合物、组合物及用途
WO2022121317A1 (zh) 1,1'-联苯-2，6-二酚类化合物及其应用
CN111848631B (zh) 一种靶向EGFR突变的吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途
CN107973788B (zh) Bbi608衍生物及其制备与用途
CN114195814B (zh) 羟基萘酮-苯硼酸类化合物、制备方法和用途
CN115703738B (zh) 含2-芳杂环取代的脲类化合物、其制备方法和用途
CN104086562B (zh) 含芳腙结构的杂环并嘧啶类化合物的制备及应用
WO2023051759A1 (zh) 三环化合物及其制备方法
Wei et al. Synthesis and biological evaluation of novel 2-arylvinyl-substituted naphtho [2, 3-d] imidazolium halide derivatives as potent antitumor agents
CN106946761B (zh) 吲哚甲酰胺类化合物及其应用
CN113801108A (zh) 蛋白激酶抑制剂及其衍生物，制备方法、药物组合物和应用
CN108456214B (zh) 含噁唑或咪唑结构的喹唑啉类化合物及其应用
CN105693729A (zh) 吲哚并[3,2-a]咔唑衍生物及其应用
CN112851679B (zh) 2，4，7-三取代嘧啶并吲哚化合物抗肿瘤作用
WO2019185033A1 (zh) 用作fgfr不可逆抑制剂的酰胺基吡唑类化合物
CN109824690A (zh) Mcl-1选择性抑制剂及其制备和用途
CN113845548B (zh) 一种喹唑啉肼二硫代甲酸酯的铂配合物及其制备方法和用途
CN115872996B (zh) 一种雌激素受体降解剂化合物及其制备方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20806809

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20806809

Country of ref document: EP

Kind code of ref document: A1